Dual STAT­3 and IL­6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL­6/IL­6R/STAT­3 axis.

Méndez-Clemente, Anibal; Bravo-Cuellar, Alejandro; González-Ochoa, Salvador; Santiago-Mercado, Maria; Palafox-Mariscal, Luis; Jave-Suárez, Luis; Solorzano-Ibarra, Fabiola; Villaseñor-García, Maria; Ortiz-Lazareno, Pablo; Hernández-Flores, Georgina

Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL6/IL6R/STAT3 axis.

Méndez-Clemente, Anibal; Bravo-Cuellar, Alejandro; González-Ochoa, Salvador; Santiago-Mercado, Maria; Palafox-Mariscal, Luis; Jave-Suárez, Luis; Solorzano-Ibarra, Fabiola; Villaseñor-García, Maria; Ortiz-Lazareno, Pablo; Hernández-Flores, Georgina.

Afiliação

Méndez-Clemente A; Doctoral Program in Biomedical Sciences Orientation Immunology, University Center for Health Sciences (CUCS), University of Guadalajara (UdeG), Guadalajara, Jalisco 44340, México.
Bravo-Cuellar A; Immunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, México.
González-Ochoa S; Doctoral Program in Biomedical Sciences Orientation Immunology, University Center for Health Sciences (CUCS), University of Guadalajara (UdeG), Guadalajara, Jalisco 44340, México.
Santiago-Mercado M; Immunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, México.
Palafox-Mariscal L; Doctoral Program in Biomedical Sciences Orientation Immunology, University Center for Health Sciences (CUCS), University of Guadalajara (UdeG), Guadalajara, Jalisco 44340, México.
Jave-Suárez L; Doctoral Program in Biomedical Sciences Orientation Immunology, University Center for Health Sciences (CUCS), University of Guadalajara (UdeG), Guadalajara, Jalisco 44340, México.
Solorzano-Ibarra F; Chronic Degenerative Diseases Research Institute Postdoctoral Stays Program for Mexico 2021, Department of Molecular and Genomic Biology, University of Guadalajara (UdeG), University Center for Health Sciences (CUCS), Guadalajara, Jalisco 44340, México.
Villaseñor-García M; Immunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, México.
Ortiz-Lazareno P; Immunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, México.
Hernández-Flores G; Immunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, México.

Oncol Rep ; 48(2)2022 Aug.

Article em En | MEDLINE | ID: mdl-35703345

Assuntos

Interleucina-6; Neoplasias da Próstata; Anticorpos Monoclonais Humanizados; Caderinas/metabolismo; Linhagem Celular Tumoral; Movimento Celular; Proliferação de Células; Óxidos S-Cíclicos; Humanos; Interleucina-6/metabolismo; Masculino; Próstata/metabolismo; Neoplasias da Próstata/tratamento farmacológico; Neoplasias da Próstata/metabolismo; Receptores de Interleucina-6; Fator de Transcrição STAT3/metabolismo; Fator A de Crescimento do Endotélio Vascular/metabolismo; Vimentina/metabolismo

Palavras-chave

IL6 receptor; STAT3; clonogenicity; invasion; migration; prostate cancer; stattic; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Interleucina-6 Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google